

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

EPIX Pharmaceuticals, Inc.  
Form SC 13G  
December 21, 2006

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. )\*

EPIX Pharmaceuticals, Inc.

-----  
(Name of Issuer)

Common Stock

-----  
(Title of Class of Securities)

26881Q 30 9

-----  
(CUSIP Number)

December 18, 2006

-----  
(Date of Event Which Requires Filing of this Statement)

Check the following box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

CUSIP NO.

13G

- 1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
GlaxoSmithKline plc
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
- (a) [ ]  
(b) [ ]
- 3 SEC USE ONLY

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
England and Wales

5 SOLE VOTING POWER  
4,266,795

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

6 SHARED VOTING POWER  
-0-

7 SOLE DISPOSITIVE POWER  
4,266,795

8 SHARED DISPOSITIVE POWER  
-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
4,266,795

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
[ ]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
13.3%

12 TYPE OF REPORTING PERSON\*  
CO

\*SEE INSTRUCTION BEFORE FILLING OUT!

CUSIP NO. 26881Q 30 9

13G

Item 1. (a). Name of Issuer:  
EPIX Pharmaceuticals, Inc.

(b). Address of Issuer's Principal Executive Offices:  
4 Maguire Road  
Lexington, MA 02421

Item 2. (a). Names of Person Filing:  
GlaxoSmithKline plc

(b). Address of Principal Business Office:  
980 Great West Road  
Brentford  
Middlesex  
TW8 9GS ENGLAND

(c). Citizenship:  
England and Wales

(d). Title of Class of Securities:  
Common stock.

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

(e). CUSIP Number:

26881Q 30 9

Item 3. Not Applicable.

Item 4. Ownership.

The information in items 1 and 5 through 11 on the cover pages (page 2) on Schedule 13G is hereby incorporated by reference.

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

Shares held by following wholly-owned subsidiaries of Reporting Person:

|                                |           |
|--------------------------------|-----------|
| Glaxo Group Limited            | 1,629,689 |
| SmithKline Beecham Corporation | 1,379,338 |
| S.R. One, Limited              | 1,257,768 |

Item 7. Identification and Classification of Subsidiaries Which Acquired the Security Being Reported on by the Parent Holding Company:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable

Item 10. Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

acquired in connection with or as a participant in any transaction having such purpose or effect.

Signature:

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set

forth in this statement is true, complete and correct.

GLAXOSMITHKLINE PLC

By: /s/ Victoria A. Whyte

-----  
Victoria A. Whyte  
Deputy Secretary

Dated: December 21, 2006